In-Body cancer killers: new CAR-T therapy targets Hard-to-Treat blood cancers

This early-stage study tests the safety of a new type of immunotherapy for people with relapsed or refractory plasma cell neoplasms, a type of blood cancer. Instead of modifying cells in a lab, the treatment creates cancer-fighting CAR-T cells directly inside the body, targeting two proteins (BCMA and GPRC5D) on the cancer cells. The study will enroll 18 participants and closely monitor side effects like cytokine release syndrome and nerve toxicity.